Virotherapy / News

Oncolytic virotherapy presented in Arab Health 2017

Rigvir holding is participating in exhibition Arab Health 2017 in Dubai, UAE. Rigvir holding's stand is located in Dubai International Convention & Exhibition Centre, Za’abeel hall, stand Z6.F30.
Arab Health is the largest gathering of healthcare and trade professionals in the MENA region, what brings together world's leading healthcare companies coming in from 70 countries.

Award "For lifetime contribution to virotherapy"

On November 17th, three Latvian scientists Rūta Brūvere, Rita Garklava and Olga Kaminska received an award - the Order "For lifetime contribution to virotherapy". Awarded scientists and doctors worked together with professor Muceniece in virotherapy laboratory since it's foundation. They donated all their lifetime to medicine and science and they also are authors of many scientific publications. During the event other professor's Muceniece fellows, who participated in development of virotherapy field was honored - Elita Šapovalova, Andris Ferdats, Olita Heisele and Vija Tīruma.

Rigvir representative office in Eurasia

Last weekend in Grozny, the capital city of Chechen Republic Eurasian representative office of Rigvir was opened. How summarize Rigvir chairman of the board – representative office is a strategic move that will help the Rigvir holding to successfully develop cooperation in Asia, the CIS countries and the neighboring regions. Grozny is known as a place with good infrastructure and is well respected in the business community, which is an important prerequisite for the creation of representative offices. Address of representative office: The Chechen Republic, Grozny, A.A.Kadyrova avenue 3/25, Grozny City.

New publication shows surprisingly positive results with oncolytic virus Rigvir

The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published. The patients of melanoma stage IV M1c, small cell lung cancer stage IIIA and histiocytic sarcoma stage IV started virotherapy with Rigvir within a few months after being diagnosed and are continuing this treatment. Patients have significantly exceeded the life expectancy, which is usual for such diagnoses. After beginning the therapy their condition stabilized and the quality of life significantly improved.

Cancer virotherapy medicine received the grant from European Commission in order to initiate the commercialization in the EU markets

European Commission within a framework of Horizon 2020 programme “Dedicated support to the biotechnology SMEs closing the gap from lab to market” awarded Latima with a grant for cancer virotherapy medicine commercialization in the EU markets. Latima is part of Rigvir holding, a group of companies, which develops and promotes cancer virotherapy worldwide.

Rigvir has been registered in Armenia

Armenian Drug and Medical Product Supervision Regulatory Authority approved the cancer treatment medication Rigvir, manufactured in Latvia. Thus developed in Latvia unique medicine, which represents a whole branch of oncology – cancer virotherapy, is now available in yet another country.Until now the cancer treatment by means of Latvian medication Rigvir was received by patients from more than 50 countries, including USA, European Union, Russia and the Middle East. For foreign patients virotherapy is generally available through medical tourism. Virotherapy is currently gaining popularity throughout the world and claiming its place in oncology.

Opening of the Global Virotherapy Cancer Clinic

On February 23rd in Jurmala, Latvia was opened the Global Virotherapy Cancer Clinic. This is the first virotherapy center in the world where patients will be offered complex virotherapy by using worldwide recognized treatment methods, diagnostics, physiotherapy, counseling therapist, music and art therapy. High level of service is guaranteed both in the clinic and remotely, when the patient will be observed at home.

Grant programme announcement

The International Virotherapy Center (IVC) was founded to co-ordinate and promote oncolytic virotherapy worldwide. The mission of the IVC is to provide cancer virotherapy to every patient who would benefit from it. One of the most important objectives of IVC is to support research in the oncolytic virotherapy field and to establish the knowledge base for the practical use of virotherapy.

2016 – the year of virotherapy

International Virotherapy Center is declaring 2016 the year of virotherapy in oncology. The main objective of the year of virotherapy is to introduce cancer patients and doctors with oncolytic virotherapy opportunities, to increase the use of virotherapy in the treatment of cancer, and to provide an effective, yet gentle for the body cancer therapy.

IV Virotherapy Conference 2015

On November 27, 2015 in Latvian National Library there took place IV Virotherapy Conference, which brought together more than 100 interested persons – oncologists, dermatologists, surgeons, scientists and other oncology experts. During the conference the most remarkable events of last year were reviewed – inclusion of Rigvir into clinical guidelines, medicine registration in Georgia, scientific publication in the authoritative medical journal Melanoma Research and rapid influx of cancer patients from abroad.